Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 282 versus GADOBUTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 282 versus GADOBUTROL.
ANGIOVIST 282 vs GADOBUTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 282 (diatrizoate meglumine and diatrizoate sodium) is a radiographic contrast agent that contains iodine, which attenuates X-rays, allowing visualization of vascular structures and organs. It increases the contrast between blood vessels and surrounding tissues by absorbing X-rays.
Gadobutrol is a gadolinium-based contrast agent (GBCA) that shortens T1 relaxation time in magnetic resonance imaging (MRI), enhancing signal intensity in tissues where it distributes. It is a paramagnetic agent that increases the relaxation rate of water protons in the vicinity of the gadolinium ion.
Iohexol (ANGIOVIST 282) is a nonionic iodinated contrast medium. Typical adult dose: 50-200 mL intravenously or intra-arterially, depending on procedure (e.g., CT: 75-150 mL IV).
0.1 mmol/kg (0.1 mL/kg) intravenous bolus; maximum dose 0.1 mmol/kg per contrast study. Repeat dosing up to 0.2 mmol/kg total during a single session may be considered on clinical judgment.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 1.24-2.23 hours (healthy); may be prolonged in renal impairment (up to 9.6 hours in severe impairment).
Renal excretion via glomerular filtration; unchanged drug: >95% within 24 hours. Biliary/fecal: <5%.
Primarily renal (90-95% unchanged within 24 hours); less than 0.3% fecal.
Category C
Category A/B
Contrast Agent
Contrast Agent